Oculis

Visionary Innovation

Annual General Meeting

May 13, 2026

Safe Harbor Statements

Cautionary note on forward-looking statements

These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements we make regarding the initiation, timing, progress and results of our preclinical studies, our clinical studies, our research and development programs, our regulatory strategy, market opportunities, our future development plans, our ability to advance product candidates into, and successfully complete clinical studies, and the timing or likelihood of regulatory filings and approvals and statements regarding the potential therapeutic benefits of our product candidates are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the possibility that Oculis may be adversely affected by economic, business, and/or competitive factors; Oculis' estimates of expenses and profitability; Oculis' ability to develop, manufacture and commercialize the product candidates in its pipeline; actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; the ability of Oculis or its partners to enroll and retain patients in clinical studies; the ability of Oculis or its partners to gain approval from regulators for planned clinical studies, study plans or sites; Oculis' ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; the success of Oculis' current and future collaborations, joint ventures, partnerships or licensing arrangements; financial position, strategy and anticipated milestones; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Oculis may from time to time file or furnish with the SEC. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Oculis

Business Update

Oculis

Successful 2025 Powering Transformative 2026

Pipeline:

- ✓ Significant advancements across all three late-stage assets
- ✓ **OCS-01** DIAMOND Phase 3 program >800 patients with DME; Focused execution and on-track for topline readout in June
- ✓ **Licaminlimab** precision medicine approach for DED gained FDA alignment; PREDICT-1 registrational trial topline readout anticipated in Q4 2026
- ✓ **Privosegtor** gained Breakthrough Therapy designation (FDA), Priority Medicines (PRIME) designation (EMA), and Special Protocol Assessment (SPA) alignment with FDA; establishing clear regulatory pathway for ON

Financial and talent capital:

- ✓ Strong balance sheet, no debt, and current cash runway into 2H 2029, excluding a CHF100m loan facility
- ✓ Expanded senior leadership team with relevant and extensive experience to drive quality and timely execution and results delivery

Oculis

Topline Results from Both DIAMOND Phase 3 Trials Expected in June 2026

Diamond
DIAbetic Macular edema patients ON a Drop



OCS-01 **NDA submission approval** for DME anticipated — **Q4 2027**

OCS-01 **NDA submission** for DME planned — **Q4 2026**

DIAMOND **Phase 3 trials topline results** in DME anticipated — **June 2026**

Last patient visit completed in DIAMOND Phase 3 program — **April 2026**

119 sites activated
>800 patients randomized

Oculis

Privosegtor, a Breakthrough Therapy and PRIME Designated Candidate, in Global Registrational PIONEER Program in Optic Neuropathies

PIONEER

Three Registrational trials in optic neuritis and NAION

MS relapses IND submission planned — **2H 2026**

PIONEER-3 in NAION initiation anticipated — **mid 2026**

PIONEER-2 in optic neuritis initiation anticipated — **1H 2026**

✓ **PIONEER-1 in optic neuritis** initiated — **Q4 2025**

PIONEER studies run concurrently to create operational synergies, improve cost efficiency, and accelerate development timelines

Oculis

Oculis Pipeline Development Strategic Evolution

Advance

OCS-01 would be the first ever topical treatment in DME, if approved

Licaminlimab precision medicine in DED

Privosegtor neuroprotection in optic neuritis

Expand

Privosegtor in neuro-ophthalmology and beyond

- **NAION**
- **MS relapses**

Explore

Potential for Privosegtor in multiple additional neuro-axonal diseases



DME diabetic macular edema, DED: dry eye disease, NAION: Non-arteritic Anterior Ischemic Optic Neuropathy MS: Multiple Sclerosis.

1. DR and DME Disease and Landscape report Nov. 2020 – 2024 market value estimate for G7, 2. DED Disease and Landscape report 2020 - 2024 market value estimate for G7, 3. MS Disease and Landscape report October 2024 – 2024 market value estimate for G7, 4. Optic nerve disorders, Transparency Market Research, 5. Global Market Insights, March 2024 https://www.gminsights.com/industry-analysis/neuroprotection-market

Oculis

A Catalyst-rich 12-month Horizon Driven by Three Core Transformative Assets in Active Registrational Programs

	Candidate	Phase 1 / Phase 2 / Phase 3	Value Catalysts
OPHTHALMOLOGY	**OCS-01 OPTIREACH®**	Diabetic Macular Edema	**DIAMOND-1 & DIAMOND-2** topline readout **June 2026** **NDA submission** for DME in **Q4 2026**
OPHTHALMOLOGY	**Licaminlimab**	Dry Eye Disease	Started **PREDICT-1** registrational trial in **Q4 2025** Topline readout from **PREDICT-1** around year-end **2026**
NEURO-OPHTHALMOLOGY	**Privosegtor**	Optic Neuritis — **Breakthrough Therapy and PRIME designations**	Started **PIONEER-1** registrational trial in **Q4 2025** Start of **PIONEER-2** registrational trial in **1H 2026**
NEURO-OPHTHALMOLOGY		NAION	Start of **PIONEER-3** registrational trial in **Mid 2026**
NEURO-OPHTHALMOLOGY		Multiple Sclerosis Relapses	Cross-reference Optic Neuritis IND for new IND submission in MS Relapses in **2H 2026**

Privosegtor, OCS-01 and Licaminlimab are investigational drugs, their safety or efficacy has not been established, and they have not received regulatory approval for commercial use in any country.

Oculis

Financial Update

Oculis

2025 Key Financial Highlights

- **Cash Position:** held cash equivalents and short-term investments of CHF 213.0 million ($268.7 million), compared to CHF 98.7 million ($109.0 million) as of December 31, 2024. Increase primarily due to equity financings gross proceeds of $210.0 million (CHF 178.9 million).
- **Research and development expenses:** 69% of total operating expenses. CHF 57.1 million ($68.7 million), compared to CHF 52.1 million ($59.1 million) in FY2024. Increase driven by OCS-01 DIAMOND program with 119 U.S. and international sites and >800 patients; Topline readout anticipated in June 2026
- **FY2025 net loss:** CHF 99.0 million or $119.1 million, compared to CHF 85.8 million ($97.4 million) for FY2024. Increase was primarily due to OCS-01 Phase 3 DIAMOND trials, increased personnel costs, and non-cash fx and warrant market-to-market adjustments.

Note: Data from 2025 Form 20-F

Oculis

Thank you

Oculis | Visionary Innovation